

Alrex[®] (loteprednol) – First-time generic

- On February 9, 2024, Armas launched an [AB-rated](#) generic version of Bausch and Lomb's [Alrex \(loteprednol\)](#) 0.2% ophthalmic suspension.
 - In addition, Bausch and Lomb launched an authorized brand alternative of Alrex on February 13, 2024.
- Alrex is approved for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.
- Loteprednol is also available generically as a [0.5% ophthalmic gel](#) and [0.5% ophthalmic suspension](#), and brand [Eysuvis[™]](#), [Inveltys[®]](#), [Lotemax[®] ophthalmic ointment](#), and [Lotemax SM](#), and brand combination with tobramycin ([Zylet[®]](#)).
 - Loteprednol 0.5% gel is indicated for the treatment of post-operative inflammation and pain following ocular surgery.
 - Loteprednol 0.5% suspension is indicated for the treatment of inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.
 - Eysuvis is indicated for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.
 - Inveltys, Lotemax, and Lotemax SM are indicated for the treatment of post-operative inflammation and pain following ocular surgery.
 - Zylet is indicated for inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.